A UK COST-UTILITY ANALYSIS OF PACLITAXEL ALBUMIN COMPARED TO SOLVENT-BASED PACLITAXEL MONOTHERAPY AND DOCETAXEL MONOTHERAPY FOR PRETREATED METASTATIC BREAST CANCER (MBC)

被引：4
|
作者：
McLeod, E. J. [1 ]
Lloyd, A. [1 ]
Samyshkin, Y. [1 ]
Prunieras, F. [2 ]
Canney, P. [3 ]
机构：
[1] IMS Hlth, London, England
[2] ABRAXIS BIOSCI, Paris, France
[3] Beatson W Scotland Canc Ctr, Glasgow, Lanark, Scotland
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)71991-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A269 / A269
页数：1
相关论文
共 50 条
  • [21] Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
    Lima, Antonio Olry de Labry
    Spacirova, Zuzana
    Fenix-Caballero, Silvia
    Hoces, Antonio Matas
    Vegas, Adrian Sanchez
    Aranzana, Manuel Cardenas
    Sierra-Sanchez, Jesus F.
    Martinez Diaz, Maria del Carmen
    del Rey, Emilio Jesus Alegre
    BREAST, 2021, 58 : 27 - 33
  • [22] Outcomes and Costs of Nanoparticle Albumin-Bound(nab-) Paclitaxel Compared to Docetaxel in Women with Pretreated Metastatic Breast Cancer
    Donatti, Christina M.
    McLeod, Euan
    Lloyd, Adam
    Prunieras, Francois J.
    QUALITY OF LIFE RESEARCH, 2010, 19 : 113 - 113
  • [23] Randomized controlled comparative clinical pharmacokinetic study of nab-paclitaxel and solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC)
    Li, S.
    Guan, Z.
    Yao, Z.
    Teng, X.
    Liao, H.
    Deng, L.
    Pan, Y.
    Yao, X.
    Hawkins, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer
    Leung, PP
    Tannock, IF
    Oza, AM
    Puodziunas, A
    Dranitsaris, G
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) : 3082 - 3090
  • [25] RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
    Zou, Denise
    Niyazov, Alexander
    Arondekar, Bhakti
    Wu, Sherry
    BREAST, 2021, 60 : 302 - 302
  • [26] Nanoparticle albumin-bound paclitaxel versus solvent-based paclitaxel in breast cancer A protocol for systemic review and meta-analysis
    Li, Bingxue
    Chen, Xinjie
    Ding, Tongjing
    Liu, Yihua
    Ma, Tingting
    Zhang, Ganlin
    Wang, Xiaomin
    MEDICINE, 2021, 100 (07) : E24514
  • [27] Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer (vol 3, pg 165, 2009)
    Guan, Zhong-Zhen
    Li, Qing Li
    Feng, Fengyi
    Jiang, Zefei
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2010, 6 (01) : 74 - 74
  • [28] Randomized phase 3 clinical trial comparing 130-nanometer albumin bound paclitaxel with solvent-based paclitaxel in Chinese patients with metastatic breast cancer
    Guan, Z.
    Feng, F. Y.
    Li, L. Q.
    Zefei, J. J.
    Shen, Z. Z.
    Yu, S.
    Feng, J.
    Huang, J.
    Yao, Z.
    Hawkins, M. J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 218 - 218
  • [29] Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial
    Schmidinger, M
    Budinsky, AC
    Wenzel, C
    Locker, GJ
    Pluschnig, U
    Brodowicz, T
    Kubista, E
    Maca, S
    Zabernigg, A
    Ilsinger, P
    Seewann, L
    Hojas, S
    Blach, M
    Zielinski, CC
    Steger, GG
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 47 (01) : 57 - 62
  • [30] Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial
    Manuela Schmidinger
    Alexandra C. Budinsky
    Catharina Wenzel
    Gottfried J. Locker
    Ursula Pluschnig
    Thomas Brodowicz
    Ernst Kubista
    Sylvia Maca
    August Zabernigg
    Peter Ilsinger
    Lothar Seewann
    Sabine Hojas
    Michaela Blach
    Christoph C. Zielinski
    Guenther G. Steger
    Cancer Chemotherapy and Pharmacology, 2001, 47 : 57 - 62
12345